DOCSLIB.ORG

Federal Register/Vol. 64, No. 184/Thursday, September 23, 1999

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 64, No. 184/Thursday, September 23, 1999 51590 Federal Register / Vol. 64, No. 184 / Thursday, September 23, 1999 / Notices DEPARTMENT OF HEALTH AND 1999. CDC reserves the right to required for waiver approval must be HUMAN SERVICES reevaluate and recategorize tests based incorporated into those existing test on the comments received in response systems for use of such test systems to Centers for Disease Control and to this Notice. be considered waived. (Pending such Prevention ADDRESSES: Comments on the modifications, the particular test system categorization of tests in this Notice already in use by a laboratory will retain Notice of Specific List for should be addressed to CLIA Federal its prior test categorization.) Categorization of Laboratory Test Register Notice, Centers for Disease Systems, Assays, and Examinations Waived Tests Marketed Under Control and Prevention, Public Health by Complexity Alternate Product Names Practice Program Office, Mail Stop F± Frequently, products which have been AGENCY: Centers for Disease Control and 11, 4770 Buford Highway, NE, Atlanta, granted waived status are later Prevention (CDC),Department of Health Georgia 30341±3724. repackaged and marketed under and Human Services (HHS). Requests for test complexity alternate product names. In these cases, ACTION: Notice with comment period. categorization should be submitted to: Attention: Test Categorization/CLIA, it is the responsibility of the SUMMARY: Regulations at 42 CFR 493.15 Centers for Disease Control and manufacturer to notify CDC and to send and 493.17, implementing the Clinical Prevention, Public Health Practice the package insert demonstrating the Laboratory Improvement Amendments Program Office, Mail Stop F±11, 4770 new labeling along with all sets of of 1988 (CLIA), Pub. L. 100±578 Buford Highway, NE, Atlanta, Georgia instructions that apply (e.g., if separate (codified at 42 U.S.C. 263a), require that 30341±3724. instructions for home use and for the Secretary provide for the Requests for waiver status should be professional use exist, send a copy of categorization of specific laboratory test submitted to: Attention: Request for both sets of instructions). Even though systems, assays, and examinations by Waiver Status/CLIA, Centers for Disease a test may be waived under one product level of complexity. The criteria for Control and Prevention, Public Health name, it is not considered waived under such categorizations also are set forth in Practice Program Office, Mail Stop F± an alternate name until it is reviewed by those regulations. 11, 4770 Buford Highway, NE, Atlanta, CDC and the manufacturer is notified of This Notice announces the addition of GA 30341±3724. the waived status. approximately 5,700 test systems, Due to staffing and resource Comments and Responses assays, and examinations that have been limitations, we cannot accept facsimile On April 11, 1997, a test list of categorized with categorization (FAX) copies of comments. Nor can we approximately 1,300 additional test notification to manufacturers between accept comments by telephone. systems, assays, and examinations January 1, 1997 and September 3, 1999. FOR FURTHER INFORMATION CONTACT: categorized by level of complexity was These categorizations were effective on Sharon Granade, (770) 488±8155. published in the Federal Register (62 the issue date of the notification letter SUPPLEMENTARY INFORMATION: All FR 17832) with a 30 day comment sent to the manufacturer. CDC invites requests for test categorization should period. CDC received no comment comments on the tests initially be submitted to CDC. Manufacturers are letters in regard to this Notice. categorized in this Notice and reserves requested to submit the package insert the right to reevaluate and recategorize and/or an Operator's Manual along with Analyte Clarification tests based on the comments received in the 510(k) or Pre-Market Approval A new analyte name, ``D-Dimer'' response to this Notice. (PMA) number for the product, if (Analyte code 1320), was created for the CDC, The Food and Drug applicable, to CDC when requesting measurement of this specific fibrin Administration (FDA) and the Health categorization. Although some products degradation product. Test systems Care Financing Administration have may now be exempt from FDA's 510(k) measuring D-Dimer, but previously agreed to the transfer of the test review process, they continue to need categorized under the broader analyte categorization responsibility to the FDA, evaluation for complexity categorization name (1904) Fibrin(ogen) Split/ and the transfer is in process. When the under CLIA. For products undergoing Degradation Products (FSP/FDP), are transfer is completed, manufacturers the 510(k) or PMA review process, CDC now listed under the new analyte name. will be able to submit premarket will not be able to issue the test The analyte name Fibrin(ogen) Split/ applications for products and requests categorization until the FDA has Degradation Products (FSP/FDP) will for complexity categorization of these completed its review process and has continue to be used for measurements products under CLIA to one agency. notified CDC of the clearance date. Test not specific to a particular degradation FDA is expected to assume test categorizations are effective as of the product. categorization responsibilities on or date of notification by CDC to the The analyte (5828) Streptococcus, about January 31, 2000. Until FDA applicant. Updates and revisions to the group A (from throat only) was deleted assumes responsibility for test CLIA test categorization list are and the test systems categorized for this categorization, CDC will continue to periodically published in the Federal analyte are now listed under the analyte perform complexity determinations and Register with an opportunity for public (5810) Streptococcus, group A. The test categorization requests should be sent to comment. CDC also maintains an system qualifier ``Direct Antigen/ the CDC. electronic list of categorized tests which Visual'', associated with this analyte, DATES: Effective date: All is available via the Internet (http:// was replaced with ``Direct from throat categorizations in this Notice were www.phppo.cdc.gov/DLS/clia/ swab.'' effective on the date of the test testcat.asp). For consistency with the listing of categorization notification letter sent to other autoantibodies, the analyte (6135) the manufacturer. Written comments on Effect of Waiver on Tests Already in Thyroid Peroxidase Autoantibodies the tests initially categorized in this Use (TPO) was replaced with (0527) Anti- Notice will be considered if they are For test systems in use prior to waiver Thyroid Peroxidase (TPO) Antibodies. received at the address indicated below, approval, any modifications to the The analyte (0708) ``Blood gases with by no later than 5 p.m. on October 25, device or instructions that were pH'' was modified to accommodate the VerDate 18-JUN-99 13:25 Sep 22, 1999 Jkt 183247 PO 00000 Frm 00002 Fmt 4701 Sfmt 4703 E:\FR\FM\A23SE3.002 pfrm01 PsN: 23SEN2 Federal Register / Vol. 64, No. 184 / Thursday, September 23, 1999 / Notices 51591 technological advances that allow direct From (6148) T11/B4 positive Orion Diagnostica Dentocult LB measurement of analytes that previously Lymphocytes to (3773) Lymphocytes, Culture Paddles (46299) were calculated. The analyte code CD2/CD19; ANALYTE: Clostridium difficile (1022) (0708) now refers to the analyte name From (6151) T4/T8 positive ``Blood gases'' and the analytes for pH, Lymphocytes to (3774) Lymphocytes, Test System, Assay, Examination: pCO2, and pO2 were assigned CD4/CD8. Becton Dickinson ColorPAC Toxin A Test (direct Ag/visual) (08170) individual analyte codes: (4982) pH, Manufacturer Listing (4983) pCO2, (4984) pO2. To avoid Biosite Triage Clostridium difficile confusion, the analyte (0731) All Body For data entry reasons, the Panel (08111) manufacturer Reference Diagnostics, Fluids (other than blood) pH was ANALYTE: Escherichia coli (1604) deleted, and the test system (04542) All Inc. is now denoted in the Test Qualitative Dipstick Color Comparison Categorization list as RDI and the Test System, Assay, Examination: pH Testing, categorized under the manufacturer International Technidyne Universal HealthWatch Quix Rapid E. deleted analyte, was reassigned to the Corp. is denoted as ITC. coli 0157 Strip Test (64043) new analyte (4982) pH. Correction ANALYTE: Gardnerella vaginalis (2212) For clarity and consistency and to Due to a data entry error, an incorrect reflect current nomenclature, the Test System, Assay, Examination: categorization for the analyte (6404) following analyte names and codes were Becton Dickinson Affirm VPIII Uric Acid on the test system (04036) changed: Microbial Identification Test Abbott Bichromatic ABA 200 was (07852) From (0735) B1 positive Lymphocytes to published as moderate complexity in Litmus Concepts Indicard Test (from (3758) Lymphocytes, CD20; the April 11, 1997 Federal Register (62 vaginal swab) (37110) From (0736) B4 positive Lymphocytes to FR 17832). The correct categorization (3759) Lymphocytes, CD19; for Uric Acid on this instrument is high ANALYTE: Helicobacter pylori (2512) From (1111) CD3(IgG1)positive complexity. Test System, Assay, Examination: Lymphocytes, (1110) CD3 positive Medical Instruments Pronto Dry Lymphocytes, and (6149) T3 positive Dated: September 16, 1999. Joseph R. Carter, (40331) Lymphocytes to (3760) Lymphocytes, Remel Selective Rapid Urea (55238) CD3; Associate Director for Management and From (1116) CD4 positive Lymphocytes Operations,
Load more

Recommended publications
  • The Association of Ffn Testing on Hospital Admissions for Preterm Labor*
    Open Journal of Obstetrics and Gynecology, 2013, 3, 126-129 OJOG doi:10.4236/ojog.2013.31024 Published Online January 2013 (http://www.scirp.org/journal/ojog/) The association of fFN testing on hospital admissions for * preterm labor Shilpa Iyer#, Thomas McElrath, Petr Jarolim, James Greenberg Brigham and Women’s Hospital, Harvard Medical School, Boston, USA Email: #[email protected] Received 5 November 2012; revised 7 December 2012; accepted 16 December 2012 ABSTRACT 1. INTRODUCTION Objective: To determine if the use of fetal fibronectin Preterm births continue to be the leading cause of infant (fFN) testing has affected hospital admissions for pre- mortality in the United States. While the infant mortality term labor. Methods: ICD-9 and CPT codes from all rate has plateaued from 2000 until the present, the per- admissions to Brigham & Women’s Hospital between centage of preterm births has increased. In 2005, 68.6% January 1, 1995 and December 31, 2010 were evaluated. of infant deaths were in preterm infants, an increase from Data recorded included total deliveries, admissions 65.6% in 2000 [1]. Along with increased rates in prema- for preterm labor (PTL) without delivery, length of turity, the cost of health care continued to skyrocket from stay (days) for PTL admissions, preterm deliveries, 2000 to 2005, and continues to increase today. In 2008, and number of fFN tests performed. The data was health care spending accounted for 16.2% of the United evaluated using a Wilcoxon test of trend and least States Gross Domestic Product, surpassing 2.3 trillion squares regression. Results: Fetal fibronectin testing dollars.
    [Show full text]
  • Rapid Ffn® Test Specimen Collection Kit
    Rapid fFN® Test Specimen Collection Kit PRD-01020 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only. The Hologic Rapid fFN Specimen Collection Kit is for use with the Rapid fFN® Tests ® ® ® (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). INTENDED USE The Rapid fFN® Test Specimen Collection Kit contains specimen collection devices consisting of a sterile, polyester-tipped swab and a specimen transport tube containing 1 mL extraction buffer. This specimen collection device is intended for collection of cervicovaginal ® ® ® specimens for the Rapid fFN Tests (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buffer is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always flush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container.
    [Show full text]
  • Fetal Fibronectin Enzyme Immunoassay and Rapid Ffn® for the ® Tliiq System
    Fetal Fibronectin Enzyme Immunoassay and Rapid fFN® for the ® TLiIQ System INFORMATION FOR HEALTH CARE PROVIDERS A TEST TO AID IN THE ASSESSMENT OF PRETERM DELIVERY RISK This brochure was prepared by Hologic, Inc. to familiarize you with the clinical interpretation of ® the Fetal Fibronectin Enzyme Immunoassay or Rapid fFN for the TLiIQ System. In conjunction with other clinical information, testing for the presence of fetal fibronectin in cervicovaginal secretions of women with suspected preterm labor and women undergoing routine prenatal care will help you and your patients gain valuable information about their pregnancies, including assessment of risk of preterm delivery. Additional copies of this brochure are available by calling 1-888-PRETERM or +1 (508) 263-2900. INTENDED USE The Fetal Fibronectin Enzyme Immunoassay and Rapid fFN for the TLiIQ System are devices to be used as an aid in assessing the risk of preterm delivery in ≤ 7 or ≤ 14 days from the time of cervicovaginal sample collection in pregnant women with signs and symptoms of early preterm labor, intact amniotic membranes, and minimal cervical dilatation (< 3 cm), sampled between 24 weeks, 0 days and 34 weeks, 6 days gestation. The negative predictive values of the Fetal Fibronectin Enzyme Immunoassay of 99.5% and 99.2%, for delivery in ≤ 7 and ≤14 days, respectively, make it highly likely that delivery will not occur in these time frames. In addition, although the positive predictive values were found to be 12.7% and 16.7% for delivery in ≤ 7 and ≤ 14 days, respectively, this represents an approximate 4-fold increase over the reliability of predicting delivery given no test information.
    [Show full text]
  • Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2
    animals Review Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2. Fetomaternal Response to Infection and Novel Diagnostic Perspectives Paulina Jawor 1,* , John F. Mee 2 and Tadeusz Stefaniak 1 1 Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wrocław University of Environmental and Life Sciences, 50-375 Wrocław, Poland; [email protected] 2 Animal and Bioscience Research Department, Teagasc, Moorepark Research Centre, P61 P302 Fermoy, County Cork, Ireland; [email protected] * Correspondence: [email protected] Simple Summary: Bovine perinatal mortality (death of the fetus or calf before, during, or within 48 h of calving at full term (≥260 days) may be caused by noninfectious and infectious causes. Although infectious causes of fetal mortality are diagnosed less frequently, infection in utero may also compromise the development of the fetus without causing death. This review presents fetomaternal responses to infection and the changes which can be observed in such cases. Response to infection, especially the concentration of immunoglobulins and some acute-phase proteins, may be used for diagnostic purposes. Some changes in internal organs may also be used as an indicator of infection in utero. However, in all cases (except pathogen-specific antibody response) non-pathogen-specific responses do not aid in pathogen-specific diagnosis of the cause of calf death. But, nonspecific markers of in utero infection may allow us to assign the cause of fetal mortality to infection and thus Citation: Jawor, P.; Mee, J.F.; increase our overall diagnosis rate, particularly in cases of the “unexplained stillbirth”. Stefaniak, T. Role of Infection and Immunity in Bovine Perinatal Abstract: Bovine perinatal mortality due to infection may result either from the direct effects of Mortality: Part 2.
    [Show full text]
  • Rapid Ffn® for the Tliiq® System Specimen Collection
    ® ® Rapid fFN for the TLiIQ System Specimen Collection Kit 71738-001 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only INTENDED USE The Hologic Specimen Collection Kit test contains specimen collection devices consisting of a sterile polyester tipped swab and a specimen transport tube containing 1 mL extraction buff er. This specimen collection device is intended for collection of cervicovaginal specimens for Hologic's in vitro diagnostic test, Rapid fFN® (fetal fi bronectin) for the TLiIQ® System. Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buff er is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always fl ush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container. 5. Specimens for fetal fi bronectin testing should be collected prior to collection of culture specimens. Collection of vaginal specimens for microbiologic culture frequently requires aggressive collection techniques that may abrade the cervical or vaginal mucosa and may potentially interfere with sample preparation.
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes
    Medical Coverage Policy Effective Date ............................................. 7/15/2021 Next Review Date ....................................... 7/15/2022 Coverage Policy Number .................................. 0099 Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes Table of Contents Related Coverage Resources Overview .............................................................. 1 Recurrent Pregnancy Loss: Diagnosis and Treatment Coverage Policy ................................................... 1 Ultrasound in Pregnancy (including 3D, 4D and 5D General Background ............................................ 2 Ultrasound) Medicare Coverage Determinations .................. 13 Coding/Billing Information .................................. 13 References ........................................................ 15 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ
    [Show full text]
  • Plasma Levels of Cellular Fibronectin in Diabetes
    Pathophysiology/Complications ORIGINAL ARTICLE Plasma Levels of Cellular Fibronectin in Diabetes SUZAN D.J.M. KANTERS, MD, PHD RINI C.J.M. FRIJNS, MD contain an extra type III structural domain JAN-DIRK BANGA, MD, PHD JAAP J. BEUTLER, MD, PHD called ED-A (3,4). Usually, Ͻ1–2% of total ALE ALGRA, MD, PHD ROB FIJNHEER, MD, PHD fibronectins in plasma consists of this cellu- lar fibronectin (5). Elevated plasma levels of cellular fibro- nectin have been reported in patients with rheumatoid vasculitis, in preeclamptic OBJECTIVE — Cellular fibronectin is an endothelium-derived protein involved in suben- women, in patients with collagen vascular dothelial matrix assembly. Elevated plasma levels of cellular fibronectin therefore reflect loss disorders, in acute trauma, in sepsis syn- of endothelial cell polarization or injury to blood vessels. Consequently, elevated plasma lev- drome, and in thrombotic thrombocy- els of circulating cellular fibronectin have been described in clinical syndromes with vascular damage, although not in diabetes or atherosclerosis. topenic purpura (5–9). These observations suggest that the intravascular accumulation RESEARCH DESIGN AND METHODS — We determined fibronectin levels in 52 of cellular fibronectin reflects injury to blood patients with type 1 diabetes, 50 patients with type 2 diabetes, 54 patients with a history of vessels. Vessel wall damage with character- ischemic stroke, 23 patients with renal artery stenosis, and 64 healthy subjects. istic endothelial extracellular matrix changes is also found in subjects with diabetes. The RESULTS — Circulating cellular fibronectin was significantly elevated in patients with dia- accumulation of proteins in the suben- betes (4.3 ± 2.8 µg/ml) compared with patients with ischemic stroke (2.0 ± 0.9 µg/ml), patients dothelial matrix in patients with diabetes is with renovascular hypertension (1.7 ± 1.1 µg/ml), and healthy subjects (1.4 ± 0.6 µg/ml).
    [Show full text]
  • (PPIR) of Rapid Fetal Fibronectin Testing for Preterm Labour in Alberta
    IHE Report Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta March 2015 (updated July 7, 2015) INSTITUTE OF HEALTH ECONOMICS The Institute of Health Economics (IHE) is an independent, not-for-profit organization that performs research in health economics and synthesizes evidence in health technology assessment to assist health policy making and best medical practices. IHE BOARD OF DIRECTORS Chair Dr. Lorne Tyrrell – Professor & CIHR/GSK Chair in Virology, University of Alberta Government and Public Authorities Ms. Janet Davidson – Deputy Minister, Alberta Health Ms. Marcia Nelson – Deputy Minister, Alberta Innovation & Advanced Education Dr. Pamela Valentine – CEO, Alberta Innovates – Health Solutions Ms. Vickie Kaminski – President & CEO, Alberta Health Services Academia Dr. Walter Dixon – Associate VP Research, University of Alberta Dr. Jon Meddings – Dean of Medicine, University of Calgary Dr. Richard Fedorak – Dean of Medicine & Dentistry, University of Alberta Dr. Ed McAuley – VP Research, University of Calgary Dr. James Kehrer – Dean of Pharmacy & Pharmaceutical Sciences, University of Alberta Dr. Braden Manns – Svare Chair in Health Economics and Associate Professor, Departments of Medicine and Community Health Sciences, University of Calgary Dr. Doug West – Chair, Department of Economics, University of Alberta Industry Ms. Lisa Marsden –VP, Cornerstone & Market Access, AstraZeneca Ms. Lauren Fischer – VP, Corporate Affairs, Eli Lilly Canada Inc. Ms. Jennifer Chan – VP, Policy
    [Show full text]
  • Peptide Pattern of Amniotic Fluid and Its
    LITHUANIAN UNIVERSITY OF HEALTH SCIENCES MEDICAL ACADEMY Egl Machtejevien PEPTIDE PATTERN OF AMNIOTIC FLUID AND ITS CORRELATION WITH PROTEIN COMPOSITION OF FETAL MEMBRANES: THE SEARCH FOR NEW POTENTIAL BIOMARKERS TO PREDICT PRETERM PREMATURE RUPTURE OF MEMBRANES Doctoral dissertation Biomedical Sciences, Medicine (06B) Kaunas, 2013 1 This doctoral dissertation was carried out at the Lithuanian University of Health Sciences in 2008–2012. Scientific Supervisor !"#$%& '"%& (<*+& ,#-+.*+& /+01+34516.& 891*:3+.1+.& ;.1<6"41*=& #$& >6+-*:& Sciences, Biomedical Sciences, Medicine – 06B) 2 TABLE OF CONTENTS ABBREVIATIONS ....................................................................................... 5 1. INTRODUCTION ................................................................................... 7 2. AIM AND TASKS OF THE STUDY ...................................................... 9 2.1. Aim of the study ........................................................................... 9 2.2. Tasks of the study ......................................................................... 9 3. NOVELTY OF THE RESEARCH ........................................................... 9 4. REVIEW OF THE LITERATURE ......................................................... 10 4.1. “Omics” technologies ...................................................................... 10 4.1.1. Human genome ........................................................................ 10 4.1.2. Transcriptome .........................................................................
    [Show full text]
  • Laboratory Testing for the Assessment of Preterm Delivery
    AACC Guidance Document on Laboratory Testing for the Assessment of Preterm Delivery AUTHORS Christopher W. Farnsworth, PhD, FAACC Alison Woodworth, PhD, DABCC, FAACC E. Rebecca Pschirrer. MD, MPH Assistant Professor of Pathology & Immunology Professor, Pathology & Laboratory Medicine Associate Professor of Obstetrics Medical Director of Clinical Chemistry Director, Core Clinical Laboratory and Gynecology and Radiology and Point of Care Testing & Point of Care Testing The Geisel School of Medicine at Dartmouth Washington University School of Medicine University of Kentucky Medical Center Hanover, NH St. Louis, MO Lexington, KY Director, Prenatal Diagnosis Program Dartmouth-Hitchcock Medical Center Erin E. Schuler, PhD Joely A. Straseski, PhD, MT(ASCP), Lebanon, NH Assistant Professor DABCC, FAACC University of Kentucky Section Chief, Clinical Chemistry Rob Nerenz, PhD, DABCC (Chair) Lexington, KY Medical Director, Endocrinology and Assistant Professor of Pathology Automated Core Laboratories and Laboratory Medicine ARUP Laboratories The Geisel School of Medicine at Dartmouth Associate Professor, Department of Pathology Hanover, NH University of Utah School of Medicine Assistant Director of Clinical Chemistry Salt Lake City, UT Dartmouth-Hitchcock Medical Center Lebanon, NH TABLE OF CONTENTS Introduction . 2 What is the pre-test probability of preterm birth in the United States and what assay performance characteristics are required to demonstrate clinical benefit? . 3 What is Fetal Fibronectin (fFN)? . 3 What are the performance characteristics of fFN in women with symptoms of preterm labor? . 3 Does fFN impact clinical outcomes in symptomatic women? . 4 What are the performance characteristics of fFN in asymptomatic women? . 4 Do tiered cutoffs improve diagnostic performance? . .. 4 Are there any trends in the number of laboratories performing fFN testing? .
    [Show full text]
  • 17 February 2021 TIME: 13.00 – 14.00 GMT (UK Time)
    Page 1 International Consortium for Harmonization of Clinical Laboratory Results Harmonization Oversight Group / Council Meeting DATE: 17 February 2021 TIME: 13.00 – 14.00 GMT (UK time) HOG Member Present Council Member Present Ian Young (chair) x Sverre Sandberg (IFCC) x Eunice Lee (Vice-Chair) x Gye Chol Kwon (KSLM) Joseph Passarelli Akira Seki (JCCLS) Steve Master Gary Myers (AACC) x Greg Miller x Tony Killeen (CAP) x Masato Maekawa Philippe Gillery (IFCC SD) x Anja Kessler Melissa Snyder x Observer Yeo-Min Yun x Loretta Doan (AACC) Amrom Obstfeld Katsuyuki Nakajima (JCCLS) Ross Molanaro YeJin Oh x Huimin Wang Susan Copple Minutes: 1) Apologies were received from Joe Passarelli, Amrom Obstfeld, Steve Master, Susan Copple 2) Minutes of the previous meeting (December 16) were approved 3) Membership: Membership remains as above. Action: Gary Myers to liaise with JCCLS to confirm their representative. 4) Consideration of new measurands Page 2 a) Gentamicin – clarification to be sought on current EQA status. Note that 2003 data (ref 2) suggests low between measurement differences, but 2017 DGKL data (ref.3) suggests high between laboratory differences. True position to be clarified before confirming status. Action: IY to ask AK about commutability of samples in DGKL scheme IY to check for any other available data b) Vitamin D – three documents to be combined into a single position statement and circulated (IY). Various groups involved in standardization activities to be advised of ICHCLR position and encouraged to collaborate (IY). c) Neisseria gonorrhoeae – agreed. Text to be added to database, clarifying that it relates to the combination of measurand and method (PCR) rather than just measurand.
    [Show full text]